Glioblastoma and Increased Survival with Longer Chemotherapy Duration

INTRODUCTION: The five-year survival rate for patients with glioblastoma (GBM) is low at approximately 4.7%. Radiotherapy plus concomitant and adjuvant temozolomide (TMZ) remains the standard of care. The optimal duration of therapy with TMZ is unknown. This study sought to evaluate the survival ben...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaoude, Dory Abou, Moore, Joseph A., Moore, Matthew B., Twumasi-Ankrah, Philip, Ablah, Elizabeth, Moore, Dennis F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: University of Kansas Medical Center 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710024/
https://www.ncbi.nlm.nih.gov/pubmed/31489102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710024/
https://www.ncbi.nlm.nih.gov/pubmed/31489102

Ejemplares similares